Niagen rises after U.S., EU rare disease designations for drug candidate

Niagen Bioscience

13/07/2026 13:49

** Shares of biotech firm Niagen Bioscience NAGE.O rise 2.6% to $3.47 premarket  
** Co says its experimental drug, NB4168, received rare disease designations in the U.S. and Europe for ataxia-telangiectasia, a rare inherited disorder that affects movement, weakens the immune system and raises cancer risk
** Says the designations provide regulatory incentives to support development of treatments for rare diseases and strengthen plans to advance NB4168 globally
** Co says there are currently no approved treatments for the disease
** NAGE says the drug is in preclinical development and plans to seek FDA clearance to begin human studies
** As of last close, NAGE was down 46.7% YTD 

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))